Depressive symptoms in patients scheduled for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: Prospective associations with morbidity and mortality

Carissa A. Low, Dana H. Bovbjerg, Steven Ahrendt, Sara Alhelo, Haroon Choudry, Matthew Holtzman, Heather L. Jones, James F. Pingpank, Lekshmi Ramalingam, Herbert J. Zeh, Amer H. Zureikat, David L. Bartlett

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose The current study examined prospective relationships between preoperative depressive symptoms and short-term (30-day morbidity and readmission) and long-term (overall survival) outcomes after hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (HIPEC + CS). Methods Ninety-eight patients scheduled for HIPEC + CS completed the Center for Epidemiologic Studies-Depression (CES-D) scale before surgery. Demographic and disease-specific factors and information about morbidity and readmission within 30 days after discharge were gathered from medical records. Survival was measured from date of surgery to death. Results Twenty-eight percent of patients had CES-D scores indicative of clinically significant depressive symptoms. Thirty-day morbidity occurred in 31.9% of patients and readmission in 22.2%. At the time of analysis (median follow-up of 49 months), 71.6% of patients were deceased, with median survival time of 11 months for those who died. After adjusting for relevant preoperative demographic and disease-specific factors, depressive symptoms were associated with greater odds of 30-day morbidity (n = 68; odds ratio, 5.50; 95% CI, 1.23 to 24.73; P = .03) and greater likelihood of 30-day readmission (n = 72; odds ratio, 5.92; 95% CI, 1.27 to 27.64; P = .02). Depressive symptoms were associated with shorter survival after adjustment for preoperative demographic and disease-specific factors (n = 87; hazard ratio, 1.88; 95% CI, 1.07 to 3.31; P = .03). This association was no longer significant when intraoperative/postoperative prognostic variables were added to the statistical model (n = 87; hazard ratio, 1.31; 95% CI, 0.72 to 2.37; P = .37). Conclusion Patients with clinically significant levels of preoperative depressive symptoms are at risk for poor clinical outcomes after HIPEC + CS, including greater risk of 30-day morbidity and readmission. Further research is warranted to determine biobehavioral mechanisms and examine whether effective interventions targeting preoperative depressive symptoms can reduce postoperative risk in this patient population.

Original languageEnglish (US)
Pages (from-to)1217-1222
Number of pages6
JournalJournal of Clinical Oncology
Volume34
Issue number11
DOIs
StatePublished - Apr 10 2016
Externally publishedYes

Fingerprint

Depression
Morbidity
Drug Therapy
Mortality
Survival
Demography
Epidemiologic Studies
Odds Ratio
Patient Readmission
Statistical Models
Medical Records
Prospective Studies
Research
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Depressive symptoms in patients scheduled for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery : Prospective associations with morbidity and mortality. / Low, Carissa A.; Bovbjerg, Dana H.; Ahrendt, Steven; Alhelo, Sara; Choudry, Haroon; Holtzman, Matthew; Jones, Heather L.; Pingpank, James F.; Ramalingam, Lekshmi; Zeh, Herbert J.; Zureikat, Amer H.; Bartlett, David L.

In: Journal of Clinical Oncology, Vol. 34, No. 11, 10.04.2016, p. 1217-1222.

Research output: Contribution to journalArticle

Low, CA, Bovbjerg, DH, Ahrendt, S, Alhelo, S, Choudry, H, Holtzman, M, Jones, HL, Pingpank, JF, Ramalingam, L, Zeh, HJ, Zureikat, AH & Bartlett, DL 2016, 'Depressive symptoms in patients scheduled for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: Prospective associations with morbidity and mortality', Journal of Clinical Oncology, vol. 34, no. 11, pp. 1217-1222. https://doi.org/10.1200/JCO.2015.62.9683
Low, Carissa A. ; Bovbjerg, Dana H. ; Ahrendt, Steven ; Alhelo, Sara ; Choudry, Haroon ; Holtzman, Matthew ; Jones, Heather L. ; Pingpank, James F. ; Ramalingam, Lekshmi ; Zeh, Herbert J. ; Zureikat, Amer H. ; Bartlett, David L. / Depressive symptoms in patients scheduled for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery : Prospective associations with morbidity and mortality. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 11. pp. 1217-1222.
@article{cea38af3663943718f33f18b71b90188,
title = "Depressive symptoms in patients scheduled for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: Prospective associations with morbidity and mortality",
abstract = "Purpose The current study examined prospective relationships between preoperative depressive symptoms and short-term (30-day morbidity and readmission) and long-term (overall survival) outcomes after hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (HIPEC + CS). Methods Ninety-eight patients scheduled for HIPEC + CS completed the Center for Epidemiologic Studies-Depression (CES-D) scale before surgery. Demographic and disease-specific factors and information about morbidity and readmission within 30 days after discharge were gathered from medical records. Survival was measured from date of surgery to death. Results Twenty-eight percent of patients had CES-D scores indicative of clinically significant depressive symptoms. Thirty-day morbidity occurred in 31.9{\%} of patients and readmission in 22.2{\%}. At the time of analysis (median follow-up of 49 months), 71.6{\%} of patients were deceased, with median survival time of 11 months for those who died. After adjusting for relevant preoperative demographic and disease-specific factors, depressive symptoms were associated with greater odds of 30-day morbidity (n = 68; odds ratio, 5.50; 95{\%} CI, 1.23 to 24.73; P = .03) and greater likelihood of 30-day readmission (n = 72; odds ratio, 5.92; 95{\%} CI, 1.27 to 27.64; P = .02). Depressive symptoms were associated with shorter survival after adjustment for preoperative demographic and disease-specific factors (n = 87; hazard ratio, 1.88; 95{\%} CI, 1.07 to 3.31; P = .03). This association was no longer significant when intraoperative/postoperative prognostic variables were added to the statistical model (n = 87; hazard ratio, 1.31; 95{\%} CI, 0.72 to 2.37; P = .37). Conclusion Patients with clinically significant levels of preoperative depressive symptoms are at risk for poor clinical outcomes after HIPEC + CS, including greater risk of 30-day morbidity and readmission. Further research is warranted to determine biobehavioral mechanisms and examine whether effective interventions targeting preoperative depressive symptoms can reduce postoperative risk in this patient population.",
author = "Low, {Carissa A.} and Bovbjerg, {Dana H.} and Steven Ahrendt and Sara Alhelo and Haroon Choudry and Matthew Holtzman and Jones, {Heather L.} and Pingpank, {James F.} and Lekshmi Ramalingam and Zeh, {Herbert J.} and Zureikat, {Amer H.} and Bartlett, {David L.}",
year = "2016",
month = "4",
day = "10",
doi = "10.1200/JCO.2015.62.9683",
language = "English (US)",
volume = "34",
pages = "1217--1222",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Depressive symptoms in patients scheduled for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery

T2 - Prospective associations with morbidity and mortality

AU - Low, Carissa A.

AU - Bovbjerg, Dana H.

AU - Ahrendt, Steven

AU - Alhelo, Sara

AU - Choudry, Haroon

AU - Holtzman, Matthew

AU - Jones, Heather L.

AU - Pingpank, James F.

AU - Ramalingam, Lekshmi

AU - Zeh, Herbert J.

AU - Zureikat, Amer H.

AU - Bartlett, David L.

PY - 2016/4/10

Y1 - 2016/4/10

N2 - Purpose The current study examined prospective relationships between preoperative depressive symptoms and short-term (30-day morbidity and readmission) and long-term (overall survival) outcomes after hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (HIPEC + CS). Methods Ninety-eight patients scheduled for HIPEC + CS completed the Center for Epidemiologic Studies-Depression (CES-D) scale before surgery. Demographic and disease-specific factors and information about morbidity and readmission within 30 days after discharge were gathered from medical records. Survival was measured from date of surgery to death. Results Twenty-eight percent of patients had CES-D scores indicative of clinically significant depressive symptoms. Thirty-day morbidity occurred in 31.9% of patients and readmission in 22.2%. At the time of analysis (median follow-up of 49 months), 71.6% of patients were deceased, with median survival time of 11 months for those who died. After adjusting for relevant preoperative demographic and disease-specific factors, depressive symptoms were associated with greater odds of 30-day morbidity (n = 68; odds ratio, 5.50; 95% CI, 1.23 to 24.73; P = .03) and greater likelihood of 30-day readmission (n = 72; odds ratio, 5.92; 95% CI, 1.27 to 27.64; P = .02). Depressive symptoms were associated with shorter survival after adjustment for preoperative demographic and disease-specific factors (n = 87; hazard ratio, 1.88; 95% CI, 1.07 to 3.31; P = .03). This association was no longer significant when intraoperative/postoperative prognostic variables were added to the statistical model (n = 87; hazard ratio, 1.31; 95% CI, 0.72 to 2.37; P = .37). Conclusion Patients with clinically significant levels of preoperative depressive symptoms are at risk for poor clinical outcomes after HIPEC + CS, including greater risk of 30-day morbidity and readmission. Further research is warranted to determine biobehavioral mechanisms and examine whether effective interventions targeting preoperative depressive symptoms can reduce postoperative risk in this patient population.

AB - Purpose The current study examined prospective relationships between preoperative depressive symptoms and short-term (30-day morbidity and readmission) and long-term (overall survival) outcomes after hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (HIPEC + CS). Methods Ninety-eight patients scheduled for HIPEC + CS completed the Center for Epidemiologic Studies-Depression (CES-D) scale before surgery. Demographic and disease-specific factors and information about morbidity and readmission within 30 days after discharge were gathered from medical records. Survival was measured from date of surgery to death. Results Twenty-eight percent of patients had CES-D scores indicative of clinically significant depressive symptoms. Thirty-day morbidity occurred in 31.9% of patients and readmission in 22.2%. At the time of analysis (median follow-up of 49 months), 71.6% of patients were deceased, with median survival time of 11 months for those who died. After adjusting for relevant preoperative demographic and disease-specific factors, depressive symptoms were associated with greater odds of 30-day morbidity (n = 68; odds ratio, 5.50; 95% CI, 1.23 to 24.73; P = .03) and greater likelihood of 30-day readmission (n = 72; odds ratio, 5.92; 95% CI, 1.27 to 27.64; P = .02). Depressive symptoms were associated with shorter survival after adjustment for preoperative demographic and disease-specific factors (n = 87; hazard ratio, 1.88; 95% CI, 1.07 to 3.31; P = .03). This association was no longer significant when intraoperative/postoperative prognostic variables were added to the statistical model (n = 87; hazard ratio, 1.31; 95% CI, 0.72 to 2.37; P = .37). Conclusion Patients with clinically significant levels of preoperative depressive symptoms are at risk for poor clinical outcomes after HIPEC + CS, including greater risk of 30-day morbidity and readmission. Further research is warranted to determine biobehavioral mechanisms and examine whether effective interventions targeting preoperative depressive symptoms can reduce postoperative risk in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=84963778157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963778157&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.62.9683

DO - 10.1200/JCO.2015.62.9683

M3 - Article

C2 - 26903574

AN - SCOPUS:84963778157

VL - 34

SP - 1217

EP - 1222

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -